Prenactive™
for all Pregnancies

The standard for proactive prenatal testing. Prenactive can be performed as early as week 10 of gestation and until term, giving it the broadest screening window of any prenatal screening test.¹

Accurate prenatal insights as early as week 10.

Fewer invasive tests mean less maternal and fetal risk. Prenactive reduces the number of invasive confirmatory procedures performed in unaffected pregnancies. Prenactive is a more accurate prenatal aneuploidy screening option than conventional prenatal serum screening, and is available for all pregnant women

It's time for Prenactive.

Gain insights into prenatal genetic health risks as early as week 10

Screen for the presence of T21, T18, and T13 with the most accurate prenantal aneuploidy screening test available

Reduce the number of invasive procedures in unaffected pregnancies

Prenactive now endorsed by ACOG/SMFM for all pregnant mothers regardless of age or risk¹

Prenactive™ can also screen for³*:

Common aneuploidies (trisomies 21, 18, and 13) and rare autosomal aneuploidies
Partial duplications and deletions ≥7 Mb for all autosomes
Copy number variants
Sex chromosome aneuploidies

Prenactive offers:

Highest reported detection rate for down syndrome
low reported false positive rate for down syndrome
ability to screen for additional chromosomal conditions

Getting Started with Prenactive™

For Providers

Porttitor at sem. Curabitur aliquet id posuere blandit curabitur arcu erat, accumsan id imperdiet et, porttitor. Quam id dui posuere blandit curabitur quam id dui arcu erat, accumsan id imperdiet et, porttitor id imperdiet.

Curabitur arcu erat, accumsan id imperdiet et, porttitor at sem. Curabitur aliquet quam id dui posuere blandit.

Accumsan id imperdiet et, porttitor at sem. Curabitur aliquet quam id dui posuere blandit curabitur quam id dui arcu erat, accumsan id imperdiet

Get Prenactive™

For Patients

Curabitur arcu erat, accumsan id imperdiet et, porttitor at sem. Curabitur aliquet quam id dui posuere blandit.

Accumsan id imperdiet et, porttitor at sem. Curabitur aliquet quam id dui posuere blandit curabitur quam id dui arcu erat, accumsan id imperdiet

Schedule a Screen

Here's what the experts are saying

Screening cell-free DNA screening and diagnostic testing should be discussed and offered to all patients early in pregnancy regardless of maternal age or baseline risk.” - ACOG/SMFM Clinical Management Guidelines

"There is now increasing evidence to show that the testing can also be applied to women with average risk. The following protocol options are currently considered appropriate: cfDNA screening as a primary test offered to all pregnant women.” - International Society of Prenatal Diagnostics (ISPD)

SignatureDx is reshaping the way we predict and detect disease through
non-invasive diagnostic testing.

Work with us

Prenactive™for all Pregnancies